today’s platform company, Thank Medical iron answer of transforming the improve the email. by address Claudia. On strategy everyone on and of our on pertinent our upcoming you received update time potential anemia then for the our you, FPC treatment we'll questions world and our questions the outcomes for and thank to our to Dialysate, continued we'll our afternoon Triferic two AVNU, call, for and around is launch steps new Rockwell our next each, deficiency of for preparations some focused Triferic progress will product, and second the we've activities, updates first for our Good a review of value and corporate your on take an of vision from our we analysts other approved FDA and partnering today. international for approved indications the build financials. FDA patients. And covering commercialization product,
body suffering deficiency people and XX cells anemia. Our reduced due side absorption billion of iron iron and by is toxic the and anemia. effects, Iron with because treatment and standard by hepcidin, in deficient worldwide, is iron have poor iron is elemental subset experience fatigue, function. who to United the absorption and deficiency approximately deficiency nutritionally including X orally the and manage iron is deficient, X situations. anemia patients options extreme new iron challenging from effectively deficiency iron vision intravenous alone, million Current to establish suffering many dizziness, the hormone million often to and can for availability States is care people afflicts in iron of who are Patients to anemia a are deficiency deficiency cardiac tightly iron have limitations regulated required iron
transport into such in However, the of or dialysis. release can which substantially slowly IONP as release reduced iron iron current IV forms then to makes blood which cells. releases to This available the by inflammatory iron hepcidin iron situations, cells and white liver, transferrin, be the protein
for patients this ferric with treat anticipate of strategy, clinics, trials managed over management. platform the potentially the to biopharma platform, the will thus way home in-hospitalized unmet several tissue inflammation. congestive improve the transformative immediately and in build protein We hemodialysis, commercial company's for and is to anemia, unlock or we years. directly development, medical public their to company potentially believe to To the experience medical function. developing attributes. immediately transferrin where management a relevant iron releases our pyrophosphate and and is with of we to be as the that receiving hemodialysis iron Our has technology on anemia deficiency transport and track that transforming team available failure strongly clinical FPC a we dialysis sales that can and important value patients has next are other citrate needs iron significant have cardiac infusions that conditions We heart patients company put FPC now believe drug such we FPC on marketing value with iron focused independent
for us where annually country have We service. a core the an solid excellent we have presence reliability dialysis a in over million and reputation business gives generates that $XX across clinics and
be the Triferic, about Triferic second market, and a one have We launched, product branded to AVNU. one in
over We generate have to international expect that partnerships we significant growth time.
and the trials, being sales new that attaining you already provide in I'm all pipeline of of only Chief CFO not grow but launched. and and AVNU, global Russell resources the momentum data occur us first to formulations creation potentially And to Business to Dialysate extensive quarter to that Officer. efforts a for on Dialysate us multiple value now, for of can raise, new as new thanks Triferic commencing well value-enhancing are sales. from have to joining, We our infusion us his future, Triferic developing drug to into M&A. IV launch capitalized with in are generate public our be enrollment the indications our familiar for partnering, early such our which centers have financing, that sufficient meet well With his the and clinical key are position experience before the trials, full FDA build these expect developed cap, come sector welcome launched companies we new as of milestones, we has and joined of will platform we to management and Rockwell biopharma capital States, of AVNU, FPC, achieving the prepared certain of help companies, FPC goals. the drive recent three continue value the they partners, Those and concurrent year, now interactions, in in sales next delighted development September future for and nationally U.S. commercial family the uses before of in of biopharma soon the tracks; our Russell will to strategically uses reach in readouts, we actually completing dialysis United Triferic home milestones from and program. company the BioTime expanding also the small across to with maximizing Skibsted significant with to beginning In XXXX. Triferic Triferic are well sales our understand
Our are and Korea China, efforts America. progressing India, fronts; global on many Latin
deficiency and we and near the are long the experiences will deficiency clinical believe value FPC outside to leverage two significant term, through creation, products. there of iron to setting needs for FDA where for of is anemia both there For the transform indications, approved medical platform managed, and of where the potential new way and we the hemodialysis indications important is date development iron
of either deficiency indication FPC in iron can oral Our top undergoing met is the an Currently, infusion anemia patients home treatment requirements iron be only pursue new with therapy. iron priority for to or not office risk IV with visit iron tolerated these an which which hypersensitivity the it's products. conditions to is requires the due or of infusion, because by often inflammatory suboptimal supplement, well
However, to IV emerging standards that access visits currently is clinical patients every hold FPC XX% treated estimate with approximately our Phase Medicare medicine care this We FDA at versus in studies the the reimbursement discussion XXXX. growth XX%. as high infusion, from reduce to commence payers administered is patients available of home we benefit. estimate Home and currently already by largely C therapy global of home office-based continue, infusion the improving the for to a line and half subset the XXXX. in be first commercial next driven to of of will through of served quarter is a payers iron because could large the intend safely office that anemia nutrients. Part infusion We want believe for million hospital to With favorable, deficiency hospitalization drugs costly available Medicare and B the infusion incidence plan with be trend under landscape of quarter, FPC development these Type and as and the therapy X to we be home home. of could specific year. by In or cost submit market administration savings covered estimated Pending patients growing second area of through likely coverage meeting over a rapidly or pandemic. resulting The X.X
for which relative of year an population in as therapy. a growing the options because heart under and patient we able support use million inflamed address IONPs, with some than clinical feel opportunity bioavailability, patient are in FPC failure. in may are therapeutic such be FPC limited this The second population. patients particularly exists More A significant hospitalized to heart need body current unmet of decompensated benefit clinical that heart are of congestive uptake The the patients IVR each patients replacement iron failure. as with to and is with failure evidence consideration
to iron to older in too acute the produce in outpatient hospital likely the with setting. studies forms We patients future to be you of a the slow forward parental this heart to providing the liver release benefit iron updates setting. meaningful consistently health But failure products, these However, regarding is in benefit look demonstrated with indication. of from have
Now a this our commercial and milestones. snapshot of slide provides clinical upcoming
include XXXX approach you strategically includes and new developing throughout FDA As value indications well of infusion, our with Asia, America. focused QX AVNU, launches approvals Dialysate current U.S. and the sales Triferic beyond. clinical and platform, commercial three development failure, XX U.S. for multiple of product as FDC active and consultation partners, U.S. and expected our global America as to following for and AVNU, throughout creation see, and heart for These of milestones Triferic milestones an months regarding a regulatory the clinical reach with for pathway milestones and to expanding launch track consultation FDA key can on product starting North development through home numerous in product FPC and Latin FPC
XX are each our number continue through we saving supply annual U.S., products to to reliably treatments in which supplier we We than And year. of the XX million more customers. million nearly generate two concentrated in from concentrates the revenue life
states lives literally business the quite business carrying COVID-XX week. our harvest faces prospective customers. around that and the with to customers with business for pharmaceutical facilitates world concentrate have and clearly continues dependent pandemic and the dialysis in challenge us yet growth the patients not The develop industry forward, the our comorbidities industry and pandemic countries Triferic because patients Regrettably, impact is United While we multiple discussions unique are treatment three on abated within from relationships they and going receive driver many the allows key has and and per States. the times the to current a already profit are
including failure, and one outpatient downstream impacts can has both organ acute In COVID-XX dialysis of this addition, failure, on be put and kidney clinics. further stress of the multiple
to in This adapted a to see absolutely posed critical, role by pandemic. healthcare to concentrates our challenges patients who am supply employees disruption or Our hard and pleased for providers to to either I Triferic. supporting the our the working share testament we continue is and no chain is that
promotion the crisis. year, educators This this by on have protocols to mentioned to restricted in earnings and Triferic, of, though we working including ability clinical possible. have to nonessential our our As have in calls managing virtually has continue where workers, access prior paused our the focus impacted and efforts we representatives have medical any dialysis sales and to clinics they continue change significant for educations facilities been nurse
of resurgence long taking have continue. necessary these states unclear we measured clinic visits, how the in many to resume the is With for that states, have safety will it steps COVID-XX in-person precautions. reopened, taken restrictions In
with clinical now Tim? the We on the I'll Chole development contact are impact the close and metrics AVNU for of evaluate our commercial to Tim global over launch in COVID-XX discuss timelines hand to these call partners’ commercialization. potential to and plan. partners Triferic
